PharmaCyte Biotech (PMCB) Short term Debt (2011 - 2021)

PharmaCyte Biotech (PMCB) posted quarterly Short term Debt of $66753.0 for Q1 2021, up 23.37% quarter-over-quarter from $54110.0 in Q4 2020.

PharmaCyte Biotech (PMCB) Short term Debt (2011 - 2021) Analysis & Trends

PharmaCyte Biotech (PMCB) has reported Short term Debt for 6 consecutive years, with $66753.0 the latest figure, recorded in Q1 2021.

In Q1 2021, Short term Debt changed N/A year-over-year to $66753.0; the TTM figure through Jan 2021 stood at $66753.0 (changed N/A YoY), while the FY2020 annual figure was $28918.0, changed N/A from the prior year.
Short term Debt grew to $66753.0 in Q1 2021 per PMCB's latest filing, from $54110.0 in the prior quarter.
Across five years, Short term Debt topped out at $66753.0 in Q1 2021 and bottomed at $28918.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	PharmaCyte Biotech	4.38 Mn	4.38 Mn	-

Download Data